本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Golfzon M: Real Swing, a realistic golf game for golfers on the go, launched on Google Play and the App Store Features real-world famous golf courses with realistic environmental elements and includes various modes such as Battlezon, challenges, and tournament play 100 premium item draw tickets, gems, gold, and premium item boxes being given away during special event to commemorate global launch SEOUL, South Korea, June 28, 2023 /PRNewswire/ -- Golfzon Co., Ltd. (Kang-su Park & Duk-hyung Choi, Co-CEOs) announced on the 28th the official global launch of Golfzon M: Real Swing, a self-developed mobile golf game, on Google Play (Android) and the App Store (iOS). Official global launch of Golfzon's mobile golf game Golfzon M Real Swing. Golfzon M is a realistic golf game that vividly captures real-life famous golf courses around the world in a mobile game. In addition to real-world courses, the game also features realistic environmental factors such as wind speed and direction along with green slope. With Golfzon M, everyone can enjoy a round of golf anytime, anywhere. Golfzon M offers a Challenge Mode for single-player gameplay, a Battlezon Mode for one-on-one match play with golfers around the world, and a Tournament Mode. For added depth, the game even features a character enhancement system where you can boost character abilities and clubs, as well as try out shaft fitting and stance adjustment. A promotional event with a ton of perks is also being held to commemorate the launch of Golfzon M. Players who log in daily to Golfzon M for seven days will receive a special reward item, and those who win after playing as a beginner in Battlezon Mode or who succeed in game-specific missions such as par, birdie, fairway landing, putt, closest to the pin, and perfect shot challenges will receive gifts such as 100 premium item draw tickets, gold, shaft exchange coupons, and gems. Chang-hoon YOO, a director of Metaverse Business Department at Golfzon, stated, "Golfzon M is an innovative mobile game made possible through Golfzon's long history of expertise and know-how in the sport of golf. We appreciate all the anticipation and interest from the many golfers who signed up through the pre-launch registration." He added, "We are delighted to bring the fun, excitement, and challenge of golf on the course and simulators to people on mobile platforms."
Lucid 與 Aston Martin 達成長期策略技術合作關係，以整合及供應 Lucid 先進的電動車動力系統及電池系統，合約價值超過 4.5 億元。 這個具有里程碑意義的協議標誌著 Lucid Group 技術部門首次締結此類合作關係，實現了擴大公司產品應用範圍的願景，並為未來更多的主流應用鋪路。 Aston Martin 能夠直接採用 Lucid 專有的電動動力系統技術，包括其超高性能的雙引擎驅動裝置，著名的電池技術，以及革命性的 Wunderbox。 Aston Martin 將會以 Aston Martin 股份及分期現金付款的方式，向 Lucid 支付技術使用費，而 Lucid 將成為 Aston Martin 的持份者之一。 此外，Lucid 與 Aston Martin 亦將就 Lucid 動力系統元件及系統進行供應安排。 加利福尼亞州紐瓦克及英國蓋登2023 年 6 月 28 日 /美通社/ -- Lucid Group, Inc.（納斯達克股票交易所：LCID）旗下汽車 Lucid Air 曾榮獲 2023 世界豪華汽車大獎，為豪華電動車體驗設立了新標準。本日該公司宣佈與標誌性英國品牌 Aston Martin 達成最終協議，建立長期的策略科技合作關係，以加速後者的高性能電氣化策略及長期增長。 Lucid 與該標誌性英國品牌 Aston Martin 達成最終協議，建立長期的策略科技合作關係，以加速後者的高性能電氣化策略及長期增長。該協議讓 Aston Martin 能夠採用 Lucid 的超高性能雙引擎驅動裝置、電池技術和 Wunderbox，並透過整合 Lucid 的專利技術獲得其技術支援。 這次是 Lucid 的首次締結此類合作關係，將讓 Aston Martin 能夠採用由 Lucid 獨家建造及生產、世界領先的電動動力系統技術，為 Aston Martin 未來的電池電動車充能。此協議亦會為 Aston Martin 提供來自 Lucid 的技術支援，方法是將後者的專有技術整合到 Aston Martin 開發的全新定制電動車平台上，另外還會提供 Lucid 的零部件。 「這次合作關係將代表著 Aston Martin 與 Lucid 之間達成具有里程碑意義的合作，Aston Martin 是歷史悠久的品牌，包括在利曼 24 小時耐力賽中獲勝，以及目前在一級方程式比賽中取得成功，而 Lucid 是矽谷在創新及技術方面最傑出的公司。」Lucid 行政總裁兼技術總監 Peter Rawlinson 表示，「根據其策略，Aston Martin 選擇了 Lucid，認識到採用其世界領先電動動力系統技術的深度好處，Lucid Air Grand Touring 所實現的突破性 516 英里 EPA 估計範圍則證實了這一點。」 「與 Lucid 達成的供應協議對 Aston Martin 在未來由電動車主導的增長來說是顛覆性的改變。」Aston Martin 執行主席 Lawrence Stroll 表示，「根據我們的策略及要求，我們選擇了 Lucid，為我們未來的電池電動車獲取行業內最高性能及最創新的技術。」 Aston Martin 經過競爭程序後，選擇了 Lucid，由後者提供先進的電動動力系統技術，包括其超高性能的雙引擎驅動裝置，著名的電池技術，以及革命性的 Wunderbox。雙引擎後驅動裝置動力強大，與扭力向量控制結合，令車輛的能力超出被動全輪驅動系統能達到的範圍。這些技術性創新的電動引擎採用了 Lucid 的微型噴嘴定子冷卻及波狀繞組、全新熱交換器技術及更高的冷卻劑流動率，以及配有升級至更高功率及擁有更準確熱邏輯的電池系統。 整體而言，該協議強調 Lucid 承諾向 Aston Martin 提供最佳的技術，以推動該公司的發展，實現在 2025 年前推出首輛純電動 Aston Martin 型號電動車的目標，並支援該品牌更廣泛的 Racing. Green. 永續發展策略。該協議亦標誌著 Lucid 的技術部門首次與汽車製造商建立合作關係，擴展了該公司的產品接觸度，並為該公司革命性的電動動力系統技術在未來有更多主流應用鋪路。本年年初，Lucid 公佈了其專為賽車而設計的功率密度電力驅動裝置衍生產品。 合作關係的開始建基於 Aston Martin 各持份者的批准，以及獲得適用的監管批准及其他慣用條件。 關於 Lucid Group Lucid 的使命是透過創造先進科技，以及以人類體驗為中心、最吸引人的豪華電動車，來啟發採用永續能源。該公司的第一輛車 Air 是先進的豪華轎車，設計以加州為靈感。EPA 官方估計 Lucid Air Grand Touring 能達到 516 英里的續航里程或 1,050 馬力。Lucid Air 在 Lucid 位於亞利桑那州卡薩格蘭德的工廠中生產，目前正向美國、加拿大、歐洲及中東地區的客戶交付產品。 媒體聯絡 media@lucidmotors.com 商標 本文包含 Lucid Group, Inc.、其子公司及其他公司的商標、服務商標、商業名稱及版權，均屬於其所有者的財產。 前瞻性陳述 本文包含「前瞻性陳述」，該等陳述乃根據 1995 年《美國私人證券訴訟改革法》的「安全港」條文而作出。該等前瞻性陳述可從所用詞彙如「估計」、「計劃」、「預期」、「預測」、「打算」、「將」、「擬」、「期望」、「預料」、「相信」、「尋求」、「目標」、「繼續」、「可能」、「或許」、「可能會」、「可能的」、「潛在」、「預計」及其他預測或表明未來事件或趨勢或非過往事實的類似陳述。這些前瞻性陳述包括，但不限於與 Lucid 的計劃相關的陳述、涉及 Lucid 與 Aston Martin 策略合作關係的期望，包括雙方完成擬議交易的可能性或能力，Lucid 的潛在得益，以及 Lucid 根據擬議條款提供技術、動力系統及電池系統的能力，Lucid 電動動力系統技術未來應用的可能性，及 Lucid 技術的前景。此等陳述基於各種假設，不管是否於本文中表明，及在 Lucid 管理層目前的預期中。此等前瞻性陳述並不打算作為擔保、保證，或對事實或可能性的明確陳述，故投資者不應過於依賴該等陳述。實際事件及情況難以或無法預測，並可能與這些前瞻性陳述有異。很多實際事件及情況是 Lucid 無法控制的。此等前瞻性陳述受到一定風險及不確定性影響，包括 Lucid 截至 2023 年 3 月 31 日的 10-Q 表格季度報告第二部分 1A 項目中，「風險因素」標題下所討論的因素，以及 Lucid 已經或將要向美國證券交易委員會提交的其他文件。若這些風險成為事實或 Lucid 的假設被證實為不正確，實際結果可能與這些前瞻性聲明所顯示的結果有實質性差異。亦可能存在 Lucid 目前不知道或目前認為不重要的其他風險，這些風險亦可能導致實際結果與前瞻性陳述內容有所不同。此外，前瞻性陳述反映了 Lucid 對未來事件的期望、計劃或預測，以及截至本文發佈之日前的觀點。Lucid 預計後續事件及發展將會對 Lucid 的評估產生變化。但是，Lucid 可能在未來某個時間點更新此等前瞻性陳述，但其明確表示沒有任何義務這樣做。此等前瞻性陳述不應被視為代表 Lucid 在本文發佈之後任何時間的評估。讀者不應過分依賴前瞻性陳述。
#QSWUR LONDON, June 28, 2023 /PRNewswire/ -- QS Quacquarelli Symonds, global higher education specialists, released the twentieth edition of the QS World University Rankings. Featuring 1500 institutions across 104 locations, it is the only ranking of its kind to emphasise employability and sustainability. The results draw on the analysis of 17.5mln academic papers and the expert opinions of 240,000+ academic faculty and employers. Massachusetts Institute of Technology celebrates twelve years at the top, the University of Cambridge retains 2nd place while the University of Oxford (3rd) climbs one position. This year, QS has implemented its largest-ever methodological enhancement, introducing three new metrics: Sustainability, Employment Outcomes and International Research Network. "Deep consultation across global higher education has empowered the QS World University Rankings to align better with Gen Z and Alpha priorities, focusing on what genuinely matters to increasingly socially conscious students in our rapidly evolving world," stated Ben Sowter, Senior Vice President, QS. QS World University Rankings 2024: Top-20 2024 2023 1 1 MIT US 2 2 University of Cambridge UK 3 4 University of Oxford UK 4 5 Harvard University US 5 3 Stanford University US 6 6= Imperial College London UK 7 9 ETH Zurich Switzerland 8 11 National University of Singapore Singapore 9 8 UCL UK 10 27 University of California, Berkeley US 11 10 University of Chicago US 12 20 Cornell University US 13 13 UPenn US 14 33 The University of Melbourne Australia =15 6= Caltech US =15 18 Yale University US =17 12 Peking University China =17 16= Princeton University US =19 45 The University of New South Wales Australia =19 41 The University of Sydney Australia © QS Quacquarelli Symonds 2004-2023 www.TopUniversities.com In this edition: 75% of Africa's universities fare better. Nine new entries. Arab Region remains increasingly competitive. Asia's top university, National University of Singapore (8th) breaks into top-10. South Korea and Japan remain strong but less prolific. Thailand and Indonesia emerging. Australia excels at global engagement. Three universities join the top-20. Canada: University of Toronto is the new national leader. China: Most improved for research impact (79% institutions rise in Citations per Faculty). ETH Zurich is continental Europe's best university for the sixteenth consecutive year. France's merged universities shine. Université PSL (24th) enters the top-25. India: New national leader, IIT Bombay, climbs into world top-150. Universidade de São Paulo (85th) takes Latin America's top-spot. UK: Shines for cross-border research collaborations. 72/90 institutions place higher. USA: UC Berkeley, named world's leader in Sustainability, breaks into top-10.
悉尼2023年6月28日 /美通社/ -- 領先的外匯及差價合約經紀商 FP Markets於 6 月 23 日在著名的 2023 年亞太區 Ultimate Fintech Awards 上榮獲「最佳交易執行」獎及「最透明經紀商」獎。這些熱門獎項標誌著 FP Markets 成為亞洲主要的外匯及差價合約經紀商。早在年初的 2023 FAME 大獎中獲得「非洲最佳差價合約經紀商」獎項，以及在 2022 年獲得了一系列令人深刻的榮譽，這些獎項標誌著 FP Markets 在 2023 年的好開始。 FP Markets Awarded ‘Best Trade Execution’ and ‘Most Transparent Broker’ at the UF Awards APAC 2023 Ultimate Fintech Awards 是行內認可的獨家基準，是各公司渴望的獎項，旨在認可 B2B 及 B2C 公司在網上交易及金融科技方面的卓越表現。這次的頒獎活動在位於泰國曼谷市中心的盛泰瀾中央世界商業中心酒店舉行，吸引了眾多參與者以及行業內領先的企業。除了幾個備受讚揚的獎項類別，各獲獎者亦在創新領導力、透明手法以及卓越服務方面獲得提名。 FP Markets 亞太區行政總裁 Nick Twidale 評論道：「在 2023 年亞太區 Ultimate Fintech Awards 贏得 『最佳交易執行』 獎及 『最透明經紀商』 獎，證實了 FP Markets 團隊的努力和奉獻精神。這些獎項亦進一步認可了 FP Markets 為客戶提供最佳交易體驗的承諾。交易執行、透明度、成本效益，教育服務及廣泛的交易平台選擇是短期及長期投資者選擇與 FP Markets 交易的關鍵優勢。這些獎項不僅標誌著該公司在亞太區的日益增長的影響力，亦強調了現今外匯交易及差價合約行業的國際影響力及認可。」 FP Markets 成立於 2005 年，是一個受多方監管的品牌，為客戶提供超過 10,000 種主要資產類別的可交易工具，結合多家頂級流動性提供商的綜合定價。此外，FP Markets 提供始終如一的低點差、疾速執行、無與倫比的 24/7 多語種客戶支持，以及適合所有交易策略和風格的各種賬戶類型 。 編輯須知 FP Markets 簡介： FP Markets 是一家受多方監管的外匯和差價合約經紀商，擁有超過 18 年的行業經驗。 該公司提供極具競爭力的銀行間外匯點差，低至 0.0 點。 交易者可以從各種領先的強大在線交易平台中進行選擇，包括 FP Markets 的 移動應用程式、 MetaTrader 4、 MetaTrader 5、 WebTrader、 cTrader和 Iress。 該公司出色的 24/7 全天候多語種客戶服務 獲得了 Investment Trends 的認可，並連續五年榮獲「最高整體客戶滿意度」獎。 FP Markets 已連續四年（2019 年、2020 年、2021 年、2022 年）在 Global Forex Awards 中被評為「全球外匯高性價比經紀商」。 FP Markets 在 2022 年 Global Forex Awards 中榮獲「歐洲最佳外匯經紀商」和「亞洲最佳外匯合作夥伴計劃」。 FP Markets 在 2022 年 Ultimate Fintech Awards 中被授予「最佳交易執行」獎。 FP Markets 在 2023 年 FAME 大獎中榮獲「非洲最佳差價合約經紀商」稱號。 有關 FP Markets 全面產品和服務的更多資訊，請瀏覽 https://www.fpmarkets.com/。
MINJUVI® (tafasitamab) provisionally approved by Therapeutic Goods Administration[1] Recent five-year follow-up data from Phase 2 L-MIND investigation showed patients treated with MINJUVI had prolonged, durable responses[2] SINGAPORE, June 28, 2023 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce that a new therapy to treat the most common type of non-Hodgkin lymphoma in adults – diffuse large B-cell lymphoma – is now approved for use in Australia. The Therapeutic Goods Administration (TGA) has provisionally approved MINJUVI® (tafasitamab) "in combination with lenalidomide followed by MINJUVI monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT)".[1] Australian lymphoma specialist and current chair of the Australasian Lymphoma Alliance, Professor Chan Cheah, said the MINJUVI approval was a great step forward for patients who had been diagnosed with DLBCL and relapsed, as the MINJUVI regimen provides an opportunity for longer-term disease management. "I think it is great news for patients," Professor Cheah said. "We do have chemotherapy options and we cure about two-thirds of patients using that approach. Unfortunately, a substantial proportion of patients either don't respond to chemotherapy, or the disease comes back after chemotherapy, and they need better treatments." MINJUVI, a CD19-targeting immunotherapy that works by attaching to a protein on the surface of B-cell lymphoma cells, stimulating an immune response against the lymphoma, is also approved in the United States [as Monjuvi® (tafasitamab-cxix)], Great Britain, Canada, Europe and other countries. Professor Cheah added: "Access to novel immune therapies like MINJUVI is really important for Australian patients. Apart from CAR-T cell therapies – and these are only applicable to a certain proportion of patients with DLBCL – there have been no novel therapies for relapsed DLBCL approved in Australia. MINJUVI has a favourable side effect profile and (combined with lenalidomide) has demonstrated a high response rate in patients with relapsed disease. We now need to see it listed on the Pharmaceutical Benefits Scheme." MINJUVI has been approved via a provisional regulatory pathway, with the TGA participating in the Modified Project Orbis initiative to accelerate availability to Australian patients. The approval was based on data from the Phase 2 L-MIND study, an open label, multi-center single arm study which evaluated its safety and efficacy in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL who were not eligible for ASCT.[1,3] Continued approval for this indication depends on verification and description of clinical benefit in the confirmatory Phase 3 frontMIND study which has completed enrollment.[4] Recently, five-year follow up data were presented which showed that MINJUVI plus lenalidomide followed by MINJUVI monotherapy provided prolonged, durable responses in adult patients with relapsed or refractory DLBCL. The overall response rate (ORR) was 57.5% with a complete response (CR) observed in 41.2% of patients, and a partial response (PR) in 16.2% of patients. The median overall survival was 33.5 months and median progression-free survival (PFS) was 11.6 months.[2] The most common adverse reactions with MINJUVI are infections (73%), neutropenia (51%), asthenia (40%), anaemia (36%), diarrhoea (36%), thrombocytopenia (31%), cough (26%), oedema peripheral (24%), pyrexia (24%), decreased appetite (22%). The most common serious adverse reactions were infection (26%) including pneumonia (7%), and febrile neutropenia (6%).[1] ST Chief Executive Officer Mr. Carlo Montagner said securing TGA approval was a key regulatory milestone for the company, noting that the therapy was synergistic with the company's mission to provide therapies that addressed unmet needs in rare patient populations. "We are delighted to successfully register MINJUVI for Australian patients and look forward to working with the lymphoma community to ensure it is available at the earliest opportunity," he said. ST markets MINJUVI under an exclusive distribution arrangement with international partner Incyte (NASDAQ: INCY). Ends. About Specialised Therapeutics Asia Headquartered in Singapore, Specialised Therapeutics Asia Pte Ltd (STA) is an international biopharmaceutical company established to commercialise new therapies and technologies to patients throughout Southeast Asia, as well as in Australia and New Zealand. ST and its regional affiliates collaborate with leading global pharmaceutical and diagnostic companies to bring novel, innovative and life-changing healthcare solutions to patients affected by a range of diseases. Its mission is to provide therapies where there is an unmet need. The company's broad therapeutic portfolio currently includes novel agents in oncology, haematology, neurology, ophthalmology and supportive care. Additional information can be found at www.stbiopharma.com About Diffuse Large B-cell Lymphoma (DLBCL) DLBCL is the most common type of non-Hodgkin lymphoma in adults worldwide[5], characterised by rapidly growing masses of malignant B-cells in the lymph nodes, spleen, liver, bone marrow or other organs. It is an aggressive disease with about 40% of patients not responding to initial therapy or relapsing thereafter[5], leading to a high medical need for new, effective therapies[6], especially for patients who are not eligible for an autologous stem cell transplant in this setting. About L-MIND The L-MIND trial was a single arm, open-label Phase 2 study (NCT02399085) investigating the combination of tafasitamab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma who had at least one, but no more than three, prior lines of therapy, including an anti-CD20 targeting therapy (e.g., rituximab), who were not eligible for high-dose chemotherapy or refused subsequent autologous stem cell transplant. The study's primary endpoint was overall response rate. Secondary outcome measures included duration of response, progression-free survival and overall survival. In May 2019, the study reached its primary completion. For more information about L-MIND, visit https://clinicaltrials.gov/ct2/show/NCT02399085. About MINJUVI® (tafasitamab-cxix) Tafasitamab is a humanized Fc-modified CD19 targeting immunotherapy. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb® engineered Fc domain, which is intended to lead to a significant potentiation of Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP), thus aiming to improve a key mechanism of tumor cell killing. MINJUVI known as Monjuvi® (tafasitamab-cxix) in the United States is approved by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved underaccelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). In Europe, Minjuvi® (tafasitamab) received conditional marketing authorization in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT). Tafasitamab is being clinically investigated as a therapeutic option in B-cell malignancies in several ongoing combination trials. Monjuvi® and Minjuvi® are registered trademarks of MorphoSys AG. Tafasitamab is co-marketed by Incyte and MorphoSys under the brand name Monjuvi® in the U.S., and marketed by Incyte under the brand name Minjuvi® in Europe and Canada. XmAb® is a trademark of Xencor, Inc. References: 1. Minjuvi® (tafasitamab). Product Information, Australia. 2. Minjuvi® (tafasitamab). Oral Abstract # CT022 Five-year follow-up of Phase 2 L-MIND study announced at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, Florida. 3. Salles, G. et al. (2020) 'Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-mind): A multicentre, prospective, single-arm, phase 2 study', The Lancet Oncology, 21(7), pp. 978–988. doi:10.1016/s1470-2045(20)30225-4. 4. clinicaltrials.gov/study/NCT04824092?term=frontMIND&intr=tafasitamab&rank=1 5. Sarkozy C, et al. Management of relapsed/refractory DLBCL. Best Practice Research & Clinical Haematology. 2018 31:209–16. doi.org/10.1016/j.beha.2018.07.014. 6. Skrabek P, et al. Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma. Current Oncology. 2019 26(4): 253–265. doi.org/10.3747/co.26.5421.
LONDON, June 28, 2023 /PRNewswire/ -- Appian Capital Advisory LLP ("Appian"), the investment advisor to long-term value-focused private capital funds that invest in mining and mining-related companies, is pleased to announce the acquisition of an 89.96% interest in the producing Rosh Pinah zinc mine, located in the Kharas region in southern Namibia, from Trevali Mining Corporation. Highlights Rosh Pinah is an operating underground zinc-lead mine with a 2,000 tonnes per day milling operation Appian plans to restart the Rosh Pinah 2.0 mine expansion project which will nearly double the mine's annual ore throughput to 1.3 million tonnes and improve safety and environmental performance Appian will retain the existing site management team and workforce, who have substantive technical expertise and understanding of the asset Rosh Pinah is one of three recent investments by Appian in the attractive zinc market, a base metal which is playing an increasingly important role in the energy transition Acquisition complements Appian's world-class portfolio of highly prospective assets located in attractive operating jurisdictions Michael W. Scherb, Founder and CEO of Appian, commented: "This acquisition marks a significant milestone for Appian as we continue to develop our world-class portfolio of highly attractive zinc assets, a critical metal that will help facilitate the upcoming energy transition. We look forward to welcoming the 450 employees at Rosh Pinah to Appian as we utilise our extensive operational and project development expertise to support the existing management team with delivering the Rosh Pinah 2.0 expansion project. We extend our gratitude to the Namibian government, our valued partners, and the local community for their trust and support." Rosh Pinah is an operating underground zinc-lead mine with a 2,000 tonnes per day milling operation, located in southwestern Namibia, approximately 800 km south of Windhoek. The mine has been in continuous operation since 1969, producing zinc and lead sulphide concentrates, as well as smaller amounts of copper, silver, and gold. Appian plans to restart the Rosh Pinah 2.0 expansion project which envisages the construction of new processing facilities, including the addition of a paste fill and water treatment plant, as well as a dedicated portal and decline to extended deposits. The project will increase mill throughput from 0.7 million tonnes to 1.3 million tonnes of ore per annum, increasing zinc equivalent production to 170 million pounds per annum, on average. Following Vedra Metals in Italy and Pine Point in Canada, Rosh Pinah is Appian's third investment in the attractive zinc market, and a strong fit with Appian's investment strategy: Controlling ownership enabling Appian to apply its best-in-class technical and operating capabilities to optimize existing operations and deliver the Rosh Pinah 2.0 expansion project safely Attractive expansion project that will significantly improve the mine's cost position and extend mine life Significant upside from near mine exploration and already identified prospects Operating mine with an experienced management team that has strong technical skills and in-depth knowledge of the asset For further information: FGS Global +44 (0)20 7251 3801 / AppianCapital-LON@fgsglobal.com Charles O'Brien, Richard Crowley, Theo Davies-Lewis About Appian Capital Advisory LLPAppian Capital Advisory LLP is the investment advisor to long-term value-focused private capital funds that invest solely in mining and mining-related companies. Appian is a leading investment advisor in the metals and mining industry, with global experience across South America, North America, Australia and Africa and a successful track record of supporting companies to achieve their development targets, with a global operating portfolio overseeing nearly 6,300 employees. Appian has a global team of 70 experienced professionals with presences in London, New York, Toronto, Vancouver, Lima, Belo Horizonte, Montreal, Dubai and Perth. For more information please visit www.appiancapitaladvisory.com, or find us on LinkedIn, Instagram or Twitter.
A12 藝術空間
Type-C
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
